1-7 of 7
David J Andorsky, MD
Close
Sort by
Journal Articles

Treatment Patterns and Outcomes of 159 Ibrutinib-Treated MCL Patients in the United States: A Retrospective Electronic Medical Record Database and Chart Review Study

Jeff Sharman, MD, Shaum Kabadi, PhD MPH, Jamyia Clark, MPH, E Susan Amirian, PhD MS, David J. Andorsky, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4163.
https://doi.org/10.1182/blood-2018-99-118848
Published: 2018
Journal Articles

Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation

Gilles Andre Salles, Wojciech Jurczak, David J. Andorsky, MD, Donald P. Quick, MD, Jack W. Singer, MD, Simran Bedi Singh, Lixia Wang, PhD, Anton Egorov, MD, Christine Gabarroca, MSc, Ruth Pettengell, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4189.
https://doi.org/10.1182/blood-2018-99-112455
Published: 2018
Journal Articles

Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma

Loretta J. Nastoupil, MD, Fontanet Bijou, MD, Vincent Ribrag, MD, Julio C. Chavez, MD, Thomas E. Witzig, MD, David J. Andorsky, MD, Leonard M. Klein, MD, Daniel Greenwald, MD, Armando Santoro, MD, Paolo Corradini, MD, Ian W. Flinn, MD PhD, Randeep Sangha, MD, Vaishalee P. Kenkre, MD, Shailaja Uttamsingh, PhD, Patrick R. Hagner, PhD, Anita K. Gandhi, PhD, Tianlei Chen, PhD, Kristen Hege, MD, Michael Pourdehnad, MD, John Kuruvilla, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1602.
https://doi.org/10.1182/blood-2018-99-114409
Published: 2018
Journal Articles

MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma

David J. Andorsky, MD, Abdulraheem Yacoub, MD, Jacob D. Bitran, MD, Jason Melear, MD, Heather D. Brooks, MD BS, BA, Kenneth A. Foon, MD, Syed Rizvi, MD, Mary Llorente, Jiahui Li, PhD, Jeff P. Sharman, MD
Journal: Blood
Blood (2016) 128 (22): 1798.
https://doi.org/10.1182/blood.V128.22.1798.1798
Published: 2016
Journal Articles

Spectrum of Expression and Biological Activity of Programmed Death Ligand 1 (PD-L1) in Non-Hodgkin’s Lymphomas

David J Andorsky, MD, Reiko Yamada, Kristopher K Steward, BS, Sven De Vos, MD, PhD, Jonathan Said, John M Timmerman, MD
Journal: Blood
Blood (2008) 112 (11): 4140.
https://doi.org/10.1182/blood.V112.11.4140.4140
Published: 2008
Journal Articles

Recombinant Interleukin-21 Plus Rituximab: Clinical Activity in a Phase 1, Dose-Finding Trial in Relapsed Low-Grade B Cell Lymphoma.

John M. Timmerman, MD, John C. Byrd, MD, David J. Andorsky, MD, Muriel F. Siadak, PA-C, Todd DeVries, PhD, Diana F. Hausman, MD, John M. Pagel, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 2577.
https://doi.org/10.1182/blood.V110.11.2577.2577
Published: 2007
Journal Articles

Baseline Physical and Mental Functioning Are Strong Predictors of Post-Stem Cell Transplant Function and Quality of Life.

David J. Andorsky, MD, Stephanie J. Lee, MD, MPH
Journal: Blood
Blood (2004) 104 (11): 3322.
https://doi.org/10.1182/blood.V104.11.3322.3322
Published: 2004